Boron Neutron Capture Therapy (BNCT) effectiveness depends on the preferential sequestration of boron in cancer cells relative to normal tissue cells. We present a novel strategy for sequestering boron using an adenovirus expressing the sodium iodide symporter (NIS). Human glioma grown subcutaneously in athymic mice and orthotopic rat brain tumors were transfected with NIS using a direct tumor injection of adenovirus. Boron bound as sodium tetrafluoroborate (NaBF 4 ) was administered systemically several days after transfection. Tumors were excised hours later and assessed for boron concentration using inductively coupled plasma atomic emission spectroscopy. In the human glioma transfected with NIS, boron concentration was more than 10 fold higher with 100 mg/kg of NaBF 4 , compared to tumor not transfected. In the orthotopic tumor model, the presence of NIS conferred almost 4 times the boron concentration in rat tumors transfected with human virus compared with contralateral normal brain not transfected. We conclude that adenovirus expressing NIS has the potential to be used as a novel boron delivery agent and should be explored for future clinical applications.
INTRODUCTION
Proposed over 70 years ago, Boron Neutron Capture Therapy, BNCT, has enormous potential to improve the survival of cancer patients by targeting cancer cells and minimizing injury to inadvertently irradiated normal tissue. [1] [2] [3] Low energy neutrons interact locally with sequestered boron, 10 B, in the target cells to produce an alpha particle, 4 He, and a lithium nucleus, 7 Li, both of which efficiently ionize the target cell's DNA because of their short track lengths. [2] [3] [4] [5] The first major problem limiting BNCT, how to deliver low energy neutrons at tissue depths sufficient for therapy, may be overcome with the use of epithermal neutrons which allow a useful penetration of at least 8 cm.
6) The second major problem limiting BNCT involves delivery of the boron to the target cells; the difficulty with delivering therapeutics to tumor cells is well documented. 7) Currently, the major limitation to the effectiveness of BNCT is how to concentrate boron-10 in cancer cells preferentially and at high enough amounts.
2,3)
The evaluation of BNCT continues because of the potential of the approach. The two most common boron delivery agents used in clinical trials with BNCT including trials designed for the treatment of malignant glioma, 8, 9) meningioma, 10) inoperable head and neck tumors 11) and oral cancer 12) are sodium borocaptate (BSH) and boronophenylalanine (BPA). A preferential distribution of boron to the tumor in the case of BSH relies on passive diffusion of BSH from blood to tumor through a disrupted blood-brain barrier (BBB). 13) Invariably, the use of BSH results in high boron concentration in blood and subsequent vascular damage during BNCT. BSH may not reach tumor cells at all if the BBB remains intact.
14) The other widely used boronated compound, BPA, is designed to yield preferential uptake in tumor by active transport across the cancer cell membrane.
15)
The transport mechanism is operative in normal cells leading to BPA accumulation in, for example, normal brain, albeit at a lower rate. There is hope that by combining BSH and BPA tumor response will improve. 16) Other approaches to improve the effectiveness of BNCT have been explored such as prolonging infusion time and dose of BPA, 17) using an x-ray boost with BNCT to deliver a sufficient therapeutic dose to target cells, 18) and developing new boron delivery agents that can selectively target tumor cells. 3) To date the clinical results from these strategies have been disappointing. BNCT effectiveness is inadequate with the compounds currently available and since delivery represents the single major limitation with BNCT, clinical breakthroughs will likely result from the advent of new strategies for boron delivery.
We present a previously unexplored and complementary approach in which a molecular pump, the sodium-iodide symporter is exploited to sequester boronated fluoride in cancer cells. The sodium iodide symporter (NIS) is a membrane glycoprotein mediating the active transport of iodide in the thyroid gland and other non thyroidal tissues, including mammary gland, stomach and salivary glands. 19) Besides iodide, NIS has been shown to transport a wide variety of monovalent anions including tetraflouroborate (BF4 -) 20) and the rate of anion transport is proportional to the number of NIS molecules in the plasma membrane. Previously, we have developed and characterized an adenoviral construct incorporating NIS. 21) Briefly, NIS gene is cloned into the E3 region of the replication-competent adenovirus (Ad5-yCD/ mutTKSR39rep) generating a new vector that co expresses NIS (Ad5-yCD/mutTKSR39rep-hNIS). The adenoviral infection results in NIS protein expression on the plasma membrane of the cells. In the current study, we measure the amounts of boron in target cancer cells targeted with adenoviral mediated NIS and determine if this approach has the potential to sequester sufficient BF4 -for effective neutron therapy.
MATERIAL AND METHODS

Animals
Male athymic mice (CD1nu/nu), six weeks of age weighing 18-20 g, were obtained from Charles River laboratory. Male Fisher 344 rats weighing 220-240 g were obtained from Jackson laboratory. Studies were conducted in an AAALAC approved facility following procedures approved by the institutional animal care and use committee.
Tumor implantation
For the human glioma studies, mice were anesthetized with 100 mg/kg ketamine, 10 mg/kg xylazine by an intraperitoneal injection. Under aseptic conditions, 1 × 10 6 U251 cells in 0.1 ml of serum free DMEM medium and equal volume of matrigel (BD Biosciences, San Jose, CA) were inoculated right hind limbs of CD1nu/nu mice subcutaneously over the gastrocnemius muscle. Tumor growth was measured three times weekly; virus was injected typically 14 days post-tumor cell implantation.
For the orthotopic brain tumor studies, Fisher 344 rats were anesthetized with 80 mg/kg ketamine, 8 mg/kg xylazine intramuscularly and positioned in a stereotactic head frame. Aseptic surgical techniques were used to open the scalp along the midline and expose the frontal and temporalis bones. A 1.0 mm burr hole was made through the skull. Care was taken not to damage the dura. The position of the injection site was 2.5 mm anterior to the bregma and 2.0 mm to the right of the midline. Ten thousand 9L glioma cells were implanted stereotactically at a depth of 3 mm in the brain parenchyma using a 10 μl syringe with a 26 gauge needle (Hamilton Co., Reno, NV). The volume injected was 5 μl. The burr hole was sealed using sterile bone wax. The scalp was sutured and the animal was allowed to recover.
Viral delivered NIS
The replication-competent adenovirus (Ad5-yCD/ mutTK SR39 rep-hNIS) incorporates hNIS, the human sodium iodide symporter. Details on the construction of Ad5-yCD/ mutTKSR39rep-hNIS have been described previously. 19) In mouse studies, the virus was injected when the tumor was 9 mm in diameter by injecting along the needle track while withdrawing the needle and without completely removing the needle, reinserting at an acute angle and repeating the procedure multiple times until the virus was sufficiently distributed. For rat tumor studies, the virus was injected directly into the tumor mass on day 14 post-tumor implantation using the same stereotactic coordinates as was used for tumor implantation. The dose of adenovirus delivered was, 1 × 10 10 viral particles which is approximately 1 × 10 8 infectious viral particles since about 1 in 100 viral particles is infectious. The virus was injected in leg tumors as uniformly as possible. In some control studies, adenovirus lacking NIS was used.
Drug administration
Ex vivo method Excised U251 tumors from mice without injected virus were mixed (spiked) with known amounts of NaBF4 (Sigma Aldrich, St. Louis, MO; MW = 109.8), 0, 30 or 100 mg/kg. The spiked samples served as confirmatory controls to provide confidence in our measurement of boron concentration in tissue. In vivo method Three days after virus injection, mice with subcutaneous tumors (n = 4) and rats with intracranial tumors (n = 6) received NaBF4 at a concentration of 100 mg/kg, by intraperitoneal injection. Two hours after drug administration, the animals were sacrificed, tumor harvested and assessed by ICP-AES for boron concentration. Control mice with tumors received an intra-tumor adenovirus injection lacking NIS followed 3 days later by a systemic administration of NaBF4 (n = 3 @ 0 mg/kg, n = 4 @ 100 mg/kg, and n = 2 @ 500 mg/kg) and sacrificed 2 hours later. Control studies with rats included the contralateral normal brains of brain tumored animals that received an intra-tumor adenovirus injection containing NIS followed 3 days later by a systemic administration of NaBF4 and sacrificed 2 hours later (n = 4), rats with tumors that did not receive an adenovirus injection and did receive a systemic administration of NaBF 4 two hours before sacrifice (n = 2), and rats without tumors that received a systemic administration of NaBF 4 two hours before sacrifice (n = 4). The average weights of the subcutaneous tumors and intracranial tumors were 0.5 g and 0.3 g respectively.
The dose of NaBF 4 selected was well tolerated in our animal models and below the LD50 in rats (http:// msds.chem.ox.ac.uk/SO/sodium_tetrafluoroborate.html).
Quantitative analysis of boron
Quantitative boron measurements were performed using inductively coupled plasma atomic emission spectroscopy (ICP-AES) (University Laboratories, Novi, MI). The frozen tissue samples were transferred into 50-ml polypropylene tubes and were completely digested with ultra high pure nitric acid at 95°C. The nitric acid solutions were analyzed for their boron content using an axial ICP-AES using a known amount of Germanium as an internal standard. Each batch of sample tissues accompanied quality control samples to monitor the background and the recovery value for boron. To monitor the background, blank samples were digested and carried throughout the analytical process; no significant concentration of boron was contributed from the analytical process. The memory effect for boron was periodically checked; no significant carryover was present, either. The recovery for boron was carried out using a laboratory control sample (LCS) in distilled water to determine the efficiency of the analytical procedure. The effect of tissue on recovery of boron in the analytical procedure was determined by spiking designated tissue samples with known amounts of boron before delivering the samples to the analytical laboratory.
Statistical considerations
Student t test was used for evaluating the results. Error bars represent standard deviation.
RESULTS
Studies are presented to demonstrate that boron could be sequestered in tumor expressing NIS using a mouse tumor model which allowed for injection of adenovirus and confirmed using orthotopic brain tumor model.
Ex vivo treatment with NaBF 4
Initially, a control study was performed to confirm that ICP-AES provided an accurate estimate of boron. A mixture of NaBF4 in several grams of brain tumor tissue at a concentration of 0, 30 and 100 mg/kg of NaBF4 resulted in ICP-AES measured boron concentrations of 0.47 ± 0.05 ppm (n = 3), 4.30 ± 0.79 ppm (n = 2), and 9.55 ± 1.91 ppm (n = 6). Figure 1 illustrates the relationship between measured boron and actual boron concentration in spiked tumor samples. The measured boron in tissue was very close to that expected based on the molecular weight of boron and NaBF 4 (approximately 10 and 110, respectively); 0.47 ppm (the detection limit of the technique) compared to the expected value of 0.00 ppm, 4 ± 1 ppm compared to the expected value of 3 ppm, and 10 ± 2 ppm versus approximately 10 ppm.
In vivo treatment with NaBF 4
The first in vivo study was to determine the boron concentration in tumor two hours following a systemic administration of NaBF 4 to mice in the absence of NIS (i.e. injection of virus lacking NIS). Figure 2 illustrates the relationship between 0 and 500 mg/kg NaBF 4 . All doses of NaBF 4 administered were well tolerated. On average, a systemic administration of 100 mg/kg NaBF 4 in the absence of NIS resulted in a tissue concentration of boron of 2.24 ± 0.94 ppm. At five times the dose of NaBF 4 , i.e. 500 mg/kg, tissue concentration of boron increased between 3 and 4 times to 7.7 ± 1.9 ppm.
Boron concentration increased significantly in tumor injected with adenovirus incorporating NIS. For example, with 100 mg/kg of NaBF 4 administered systemically to mice having 3 days previously received a direct intra-tumor injection of adenovirus incorporating NIS, the mean concentration of boron measured was 23.9 ± 12.1 ppm (Fig. 3) compared with the mean concentration in tumor without virus injection was 2.24 ± 0.94 ppm. There was an 11 ± 7 (ratio ± maximum probable error) fold increase of boron in tumor containing virus incorporating NIS compared to tumor with virus lacking NIS.
NaBF 4 administration in an orthotopic brain tumor
The mean concentration of boron in the tumor carrying virus incorporating NIS was significantly higher at 3.8 ± 0.6 ppm (p < 0.05) than the mean concentration of boron measured in tumor without injected virus, 1.8 ± 0.2 ppm. The average concentration of boron in the contralateral normal brain tissue was 0.94 ± 0.5 ppm (Fig. 4) . The results demonstrate that injection of virus expressing NIS increased the uptake of boron into the tumor by a factor of almost four compared to contralateral normal brain tissue.
DISCUSSION
In the present study virus containing NIS was used to deliver preferentially boron into target cells notwithstanding the need to optimize the injection strategy, the dose and timing of NaBF4 and virus. In addition to showing an increase in uptake by the cells infected by adenovirus containing NIS, the normal brain surrounding the tumor had significantly less boron (Fig. 4) . The results presented demonstrate the potential of NIS to sequester BF4 -and provide a new strategy to address a major factor limiting the therapeutic effectiveness of BNCT, the ability to achieve sufficient tumor/ brain boron levels.
The uptake of BF4 -by NIS expressing cells has been reported in the 1960's by Anbar and co-workers using animal models. 22, 23) They showed that BF4 -did not accumulate in appreciable quantities in organs lacking NIS. In our study, we noted boron accumulation in the tumor which increased significantly due to introduction of NIS (p < 0.05). Also the boron content in the surrounding normal brain with intact BBB was significantly less. This is important as it may decrease injury to normal brain during neutron irradiation and also may reduce toxicity associated with the use of NaBF4.
An useful boron delivery strategy for effective BNCT should result in high relative boron levels in tumor compared to normal brain, have low systemic toxicity, and be able to deliver at least 10-30 ppm (μg/g) or 10 9 atoms of 10 B into the tumor. 24, 25) In the present study, the mean concentration of boron measured in subcutaneous human tumor with NIS was 23.9 ± 12.1 ppm, 11 times that found in tumor not expressing NIS. The orthotopic rat brain tumor model yielded a mean boron concentration of 3.8 ± 0.6 ppm and a tumor-tonormal tissue ratio of approximately 4:1. More NaBF4 was expected in tumor compared to normal brain because the replication competent adenovirus which confers NIS expression in transfected cells replicates preferentially in cancer cells compared to normal tissue cells. Similarly, more NaBF4 was expected in the human tumor compared to the rat tumor because the human adenovirus infects human cells better than non-human cells. 26, 27) Despite the limitations of the models, the approach provides preferential transport of Fig. 3 . Effect of NIS on boron sequestration. Increased boron concentration resulted in tumors injected with adenovirus expressing NIS compared to adenovirus not containing NIS after the administration of 100 mg/kg NaBF4. U251 tumors growing intramuscularly in the hind legs of athymic CD-1 nu/nu mice were infected with adenovirus incorporating NIS. Control mice were transfected with adenovirus lacking NIS, labeled "No NIS". Tumors on average had 11 times the boron concentration if injected with adenovirus containing NIS. Fig. 4 . Effect of NIS on boron sequestration in an orthotopic 9L rat brain tumor. Boron uptake is four-fold higher in brain tumors infected with adenovirus expressing NIS compared to brain tumors without NIS and normal brain after administration of 100 mg/kg of NaBF4. 10 B into NIS expressing tumor cells and the values of boron are comparable to the mean tumor concentration and tumor to normal tissue ratio of boron achieved in recent clinical studies. 28, 29) It is of note that as an anti-cancer therapy, the use of replication competent adenovirus may provide the additional advantage of direct destruction of tumor cells 30) and indeed it is arguable that higher levels of boron are possible if a replication defective virus had been employed. Another advantage of using NIS is the ability to image cells expressing the symporter. Previously we have shown that NIS can be used to non-invasively image organs expressing the NIS using pertechnetate ion ( 99m TcO 4 -). 21) This suggests the potential to image regions of NIS expression in tumor before treatment with neutrons to aid treatment planning. Finally, since NIS is naturally expressed in 80% of breast tissue 31) and 30% of metastatic breast cancer, 32) there is the potential that BF4 -can be used as a potential source of boron for treating breast tumors and/or metastatic breast cancer perhaps especially when spread to the brain, without the need for adenovirus-mediated delivery of NIS.
Various techniques could be explored to improve distribution and increase the amount of NIS/BF4 -delivered to tumor. This includes improving the intracranial virus injection strategy to deliver increased or homogenous distribution of NIS. Also the amount of NIS expression has been shown to improve after administration of agents like dexamethasone and retinoic acid. 33) Since NaBF4 doesn't seem to enter normal brain with intact BBB, this approach can be combined with conventional drugs like BPA to increase the amount of boron in tumor without additional toxicity.
One limitation of the study is the lack of radiobiological study proving that NaBF4 is in fact therapeutically useful during BNCT. But we report a novel strategy of delivering intracellular boron and our method could potentially be used to deliver boron to different organ sites as the transportation of boron into the cell is dependent on injected virus carrying NIS. Even though we were able to achieve high tumor/ normal tissue boron concentration in the orthotopic brain tumor model, the absolute amount of boron was significantly less compared to values reported in the literature. However, the absolute concentration of boron in subcutaneous tumors with NIS was as high as 64 ppm (mean concentration of 23.9 ± 12.1 ppm). This may be due to the fact that we had more control injecting virus into subcutaneous tumor and hence increased NIS. The use of replication competent virus could lead to cytotoxic activity and hence may decrease the amount of boron in the tumor. Optimizing the timing of virus injection and NaBF4 administration could improve the tumor boron levels. Another strategy to achieve higher boron content would be the use of replication defective virus.
In conclusion, we demonstrate the proof-of-concept that adenovirus incorporating NIS allows for preferential delivery of boron to the target tumor. Further studies are warranted to optimize the dose and timing of NaBF4 administration, improve intracranial virus injection strategy, use of replication defective virus and combining NaBF 4 with conventional boron delivery agents.
